Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases
Open Access
- 28 July 2020
- Vol. 12 (8), 2109
- https://doi.org/10.3390/cancers12082109
Abstract
Bone metastasis is a major cause of morbidity within solid tumours of the breast, prostate, lung and kidney. Metastasis to the skeleton is associated with a wide range of complications including bone fractures, spinal cord compression, hypercalcaemia and increased bone pain. Improved treatments for bone metastasis, such as the use of anti-bone resorptive bisphosphonate agents, within post-menopausal women have improved disease-free survival; however, these treatments are not without side effects. There is thus a need for biomarkers, which will predict the risk of developing the spread to bone within these cancers. The application of molecular profiling techniques, together with animal model systems and engineered cell-lines has enabled the identification of a series of potential bone-metastasis biomarker molecules predictive of bone metastasis risk. Some of these biomarker candidates have been validated within patient-derived samples providing a step towards clinical utility. Recent developments in multiplex biomarker quantification now enable the simultaneous measurement of up to 96 micro-RNA/protein molecules in a spatially defined manner with single-cell resolution, thus enabling the characterisation of the key molecules active at the sites of pre-metastatic niche formation as well as tumour-stroma signalling. These technologies have considerable potential to inform biomarker discovery. Additionally, a potential future extension of these discoveries could also be the identification of novel drug targets within cancer spread to bone. This chapter summarises recent findings in biomarker discovery within the key bone metastatic cancers (breast, prostate, lung and renal cell carcinoma). Tissue-based and circulating blood-based biomarkers are discussed from the fields of genomics, epigenetic regulation (micro-RNAs) and protein/cell-signalling together with a discussion of the potential future development of these markers towards clinical development.This publication has 153 references indexed in Scilit:
- Detection of circulating tumor cells in different stages of prostate cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2013
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Activation of the Imprinted Dlk1-Dio3 Region Correlates with Pluripotency Levels of Mouse Stem CellsOnline Journal of Public Health Informatics, 2010
- Circulating tumor cells: a window into cancer biology and metastasisCurrent Opinion in Genetics & Development, 2010
- DIANA-mirPath: Integrating human and mouse microRNAs in pathwaysBioinformatics, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- microRNAs exhibit high frequency genomic alterations in human cancerProceedings of the National Academy of Sciences of the United States of America, 2006
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Mechanisms of Bone MetastasisThe New England Journal of Medicine, 2004